Literature DB >> 24854371

ANCA-positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA): outcome and long-term follow-up of 50 patients from a single Polish center.

Barbara M Sokolowska1, Wojciech K Szczeklik, Anna A Wludarczyk, Pawel P Kuczia, Bogdan A Jakiela, Jolanta A Gasior, Sylwia R Bartyzel, Piotr A Rewerski, Jacek Musial.   

Abstract

OBJECTIVES: The aim of the study was to compare the course of the disease and treatment outcomes in ANCA-positive and ANCA-negative eosinophilic granulomatosis with polyangiitis (EGPA) patients from one Polish tertiary referral centre.
METHODS: Retrospective and prospective cohort study carried out on 50 patients treated in our department between 1998 and 2012. EGPA diagnosis was based on the American College of Rheumatology (ACR) criteria. Treatment protocol was based primarily on the predictive Five Factor Score (FFS) scale. Clinical characteristics of the patients, general symptoms, organ involvement, treatment regimen, and follow-up outcomes were evaluated according to ANCA status.
RESULTS: Fifteen ANCA-positive patients and 35 ANCA-negative patients were enrolled. At the time of diagnosis ANCA-positive patients had a higher incidence of renal involvement (53% vs. 7.7%; p<0.001), skin involvement (93.3% vs. 57.1%; p=0.03), and peripheral neuropathy in the form of mononeuritis multiplex (60% vs. 25.7%; p=0.021). ANCA-negative patients had significantly more frequent cardiac manifestations, but only with regard to the entire period of follow-up (68.6% vs. 33.3%; p=0.021). Patients in both groups were under the same treatment regimens, however steroid dose necessary to maintain remission of the disease was significantly higher in the group of ANCA-positive patients (9±2.5 vs. 7.4±1.9 mg/day of methylprednisolone; p=0.023). The presence of ANCA did not affect the frequency of relapses.
CONCLUSIONS: Our results confirm the differences in clinical disease presentation based on ANCA status and indicate that ANCA-positive patients should be treated more aggressively.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24854371

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  19 in total

1.  Clinical course and outcomes of childhood-onset granulomatosis with polyangiitis.

Authors:  Karen E James; Rui Xiao; Peter A Merkel; Pamela F Weiss
Journal:  Clin Exp Rheumatol       Date:  2016-10-06       Impact factor: 4.473

Review 2.  Anti-neutrophil cytoplasmic antibodies and their clinical significance.

Authors:  Supaporn Suwanchote; Muanpetch Rachayon; Pongsawat Rodsaward; Jongkonnee Wongpiyabovorn; Tawatchai Deekajorndech; Helen L Wright; Steven W Edwards; Michael W Beresford; Pawinee Rerknimitr; Direkrit Chiewchengchol
Journal:  Clin Rheumatol       Date:  2018-03-10       Impact factor: 2.980

3.  The clinical features and treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in Turkey: one or two distinct diseases?

Authors:  Emine Duran; Ozge Can Bostan; Emre Bilgin; Saltuk Bugra Kaya; Ertugrul Cagri Bolek; Serdar Ozer; Ebru Damadoğlu; Sule Apras Bilgen; Gul Karakaya; Omer Karadag
Journal:  Intern Emerg Med       Date:  2021-10-10       Impact factor: 3.397

Review 4.  ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients.

Authors:  Divi Cornec; Emilie Cornec-Le Gall; Fernando C Fervenza; Ulrich Specks
Journal:  Nat Rev Rheumatol       Date:  2016-07-28       Impact factor: 20.543

5.  Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America.

Authors:  Irena Doubelt; David Cuthbertson; Simon Carette; Sharon A Chung; Lindsy J Forbess; Nader A Khalidi; Curry L Koening; Carol Langford; Carol A McAlear; Larry W Moreland; Paul A Monach; Philip Seo; Ulrich Specks; Robert F Spiera; Jason M Springer; Antoine G Sreih; Kenneth J Warrington; Peter A Merkel; Christian Pagnoux
Journal:  ACR Open Rheumatol       Date:  2021-05-25

Review 6.  Cutaneous manifestations of acute kidney injury.

Authors:  Gavin A Esson; Amaani B Hussain; Simon J Meggitt; Nick J Reynolds; John A Sayer
Journal:  Clin Kidney J       Date:  2021-12-09

Review 7.  Recent advances in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  B Lazarus; G T John; C O'Callaghan; D Ranganathan
Journal:  Indian J Nephrol       Date:  2016 Mar-Apr

8.  Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series.

Authors:  Aikaterini Detoraki; Eugenio Tremante; Remo Poto; Emanuela Morelli; Giuseppe Quaremba; Francescopaolo Granata; Antonio Romano; Ilaria Mormile; Francesca Wanda Rossi; Amato de Paulis; Giuseppe Spadaro
Journal:  Respir Res       Date:  2021-06-23

9.  Subtypes in eosinophilic granulomatosis with polyangiitis classified according to rheumatoid factor.

Authors:  Jun Inamo; Yuko Kaneko; Yuichiro Ota; Tsutomu Takeuchi
Journal:  Clin Rheumatol       Date:  2019-07-17       Impact factor: 2.980

10.  Long-term outcomes in antineutrophil cytoplasmic autoantibody-positive eosinophilic granulomatosis with polyangiitis patients with renal involvement: a retrospective study of 14 Chinese patients.

Authors:  Yinghua Chen; Yuemei Ding; Zhengzhao Liu; Haitao Zhang; Zhihong Liu; Weixin Hu
Journal:  BMC Nephrol       Date:  2016-07-26       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.